Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial
-
Published:2022-12
Issue:
Volume:54
Page:101703
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
McMahon James H.ORCID, Lau Jillian S.Y., Coldham Anna, Roney Janine, Hagenauer Michelle, Price Sally, Bryant Mellissa, Garlick Jill, Paterson Anne, Lee Sue J., O'Bryan Jess, Hearps Anna, Tachedjian Gilda, Pinskier Henry, Phillips Cameron, Garrow Stuart, Pinskier Nathan, Melvin RobertORCID, Blakeway Luke, Wisniewski Jessica A., Byers Sally, Badoordeen Gnei Z., Pereira Stephanie, Pragastis Katherine, Trubiano Jason A., Chua Kyra Y.L., Kainer Marion, Molton James S.ORCID, Gardiner Bradley J.ORCID, Pierce Anna B., Cheng Allen, Rogers Benjamin A., Peleg Anton Y.
Reference30 articles.
1. Dexamethasone in hospitalized patients with Covid-19;Group;N Engl J Med,2021 2. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial;Marconi;Lancet Respir Med,2021 3. Virology, transmission, and pathogenesis of SARS-CoV-2;Cevik;BMJ,2020 4. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19;Hammond;N Engl J Med,2022 5. Early remdesivir to prevent progression to severe Covid-19 in outpatients;Gottlieb;N Engl J Med,2022
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|